“Transforming venom, one of nature’s most powerful bioactive substances, into hope for humanity.” That is the bold mission driving Veneno Technologies. Led by President and CEO Takatoshi Kuno, the company is working to break through the limitations of conventional drug discovery with its proprietary peptide engineering technologies. Together with partners around the world, Veneno is pursuing the realization of One Health, an integrated vision of protecting the health of people, animals, and the environment. Here, we take a closer look at Kuno’s passion and vision.
Where It All Began: Unlocking the Vast Potential of DRPs Found in Nature’s Venoms
The story of Veneno Technologies began with a deep respect for nature and an intense scientific curiosity. Kuno focused on venoms from spiders, scorpions, and other organisms, substances refined over hundreds of millions of years of evolution. These venoms contain molecules that act on highly specific biological targets with remarkable precision, functioning almost like nature’s own precision tools. Yet because of their structural complexity, they have long been considered extremely challenging to synthesize or mass-produce using conventional technologies.
Kuno believed that this unexplored frontier held the key to addressing diseases that existing medicines could not adequately treat. What others saw as impossible, he saw as opportunity: to control and apply complex disulfide-rich peptides (DRPs) that had long been considered beyond practical reach, and to bring them from research into real-world use. That conviction remains the driving force behind everything Veneno does.
A Proprietary Technology Platform as Veneno’s Strategic Competitive Edge
Veneno Suite, a World-Leading High-Throughput Platform
Veneno’s greatest strength lies in its proprietary peptide synthesis and screening platform, developed in-house to deliver exceptional speed and efficiency. Kuno’s ambition has never been limited to scientific discovery alone. He has devoted himself to building the systems needed to turn breakthrough research into viable industrial assets.
Using its unique platform, Veneno can generate complex bioactive peptides in a much shorter time frame and with higher quality than conventional methods, which often require years. This platform gives young researchers the freedom to explore boldly, without being paralyzed by the fear of failure. The accumulation of those repeated trials and insights is creating a body of know-how that is difficult for others to replicate.Kuno sees this technology not only as a research engine, but as a shared language for connecting with the world’s best minds. That is why Veneno actively promotes joint research not only for internal development, but also with global pharmaceutical companies and academic institutions. As a frontrunner in the field, the company aims not simply to compete within the biotech ecosystem, but to help reshape it.
Looking Ahead: Realizing One Health and Passing Science to the Next Generation
“Our challenge does not stop at drug discovery alone.” The future Kuno envisions is grounded in the concept of One Health, encompassing not only human medicine, but also animal health and the sustainability of the global environment. The potential applications of DRPs are vast, including areas such as environmentally responsible crop protection solutions that could serve as alternatives to conventional chemical pesticides.
Because Kuno has worked across both academia and industry, he places special importance on creating an environment where young researchers can feel that their work is truly making a difference in the world. At Veneno, members with diverse nationalities and areas of expertise come together around the same table to discuss ideas and create new value.
Under Kuno’s leadership, Veneno Technologies is striving to turn each single drop of venom into a source of healing and hope for the world. With the power of science, the company continues its challenge to shape a better future, not only for today, but for the next hundred years.